Design (Testphase)
Risk & Weakness
Altman Z: Distress Zone
92
Findings
August 3, 2026
last calculated
Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Altman's bankruptcy early warning in its purest form: the Z″-Score is in the distress zone (< 1.1) in both the most recent AND every available quarter, plus weak interest coverage (< 3). Unlike the stricter Going Concern scanner (which additionally requires negative operating cash flow), this scanner shows every stock that trades permanently in the red zone. Fundamentally healthy stocks (Piotroski ≥ 5 or Fundamental Rating ≥ 55 out of 100) are excluded via the global short filters. Source: fundamental data.
Global filters: market cap of $50B or less (mega caps are cut from every scanner); 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Fundamental Rating ≥ 55 out of 100) are excluded.
🔔 Watch scanner
Terms in This Scanner Explained
(18)
- ADR (Average Daily Range)
- The average daily swing of a stock in percent - measured over 10 or 30 trading days (columns "ADR 10D/30D"). An ADR of 5% means: on a normal day the gap between the intraday low and high runs about 5%. Traders look for movement - that is why stocks with an ADR under 1% are filtered out globally. Not to be confused with ADR meaning "American Depositary Receipt" (a US certificate for foreign shares) - here ADR always means the daily swing.
- AI Classification
- Our company-by-company assessment of the AI boom based on SEC filings (the last four quarterly 10-Q reports and two annual 10-K reports): "Sells AI" (AI is a revenue source), "Threatened" (AI is a concrete business risk), "Uses AI" (operational use), or "Neutral" (no material AI exposure). Every classification requires at least two direct quote citations - otherwise the column shows "-". Not a quality judgment or a buy recommendation; the full file is on the stock page, methodology at /stocks/ai-rating-methodology.
- Altman Z-Score
- A bankruptcy early-warning system developed by Edward Altman: several balance-sheet ratios are combined into one score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. Values from 2.6 up are considered a safe zone, values below 1.1 a distress zone with elevated bankruptcy risk; in between lies a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
- Analysis (Full Company Analysis)
- If the Analysis column shows "Read," there is an in-depth TickerGuard company analysis for this stock: business model, scanner findings, quarterly results, evidence from SEC filings, plus opportunities and risks. One click opens it directly.
- Avg/Yr 3Y (Average Annual Return)
- The stock's average annual return over the past 3 years. Shows at a glance whether a stock delivers over the long run or just had a short hot streak.
- Earnings Date
- The date of the next quarterly earnings report. Price gaps in either direction are common around this date - that is why we color it red when it is 7 days away or less, and yellow when it is 14 days away or less: elevated risk for fresh positions.
- EPS (Earnings per Share)
- Quarterly earnings divided by the number of shares outstanding. The most important growth metric: if EPS rises strongly over several quarters, the company is earning more money per share.
- Free Cash Flow (FCF)
- Operating cash flow minus capital expenditures - the money left over for everything else (debt paydown, acquisitions, or buybacks). Consistently positive free cash flow is one of the most honest signs of a healthy business model.
- Funda Rating (Fundamental Rating A+ to F)
- Our proprietary fundamental rating from 0 to 100 points with a school-grade rank from A+ to F. 50 points is the average across the universe, 100 the best possible score. Every stock is scored against all others by percentile: growth in earnings and revenue, earnings surprises, analyst estimates, and quality criteria such as margins, cash flow, and balance-sheet strength. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below — A/A+ are the fundamentally strongest stocks in the universe.
- Going Concern
- The assumption in a company's annual report that it can continue operating. If auditors raise "substantial doubt" about this, it is one of the sharpest warnings there is - the company could run out of cash.
- Long / Short
- Long = betting on rising prices (buying the stock). Short = betting on falling prices (selling borrowed shares to buy them back cheaper later). Our short scanners are warning or watch lists - not buy candidates.
- Market Capitalization (Mkt Cap)
- The market value of the company: share price x total shares outstanding, shown here in billions of dollars. Micro caps (< $0.3B) are small and volatile, mega caps (> $200B) are heavyweights. Our scanner universe is deliberately capped at $50B - we look for stocks with room to run.
- Net Margin
- How much of revenue is left as profit? Net income divided by revenue, in percent. A 20% margin means: out of every dollar of revenue, 20 cents is left as profit. Rising margins are a strong quality signal.
- Operating Cash Flow (OCF)
- The cash that actually flows into the company from day-to-day operations - without accounting effects such as depreciation. A company can report book profits while still burning cash; operating cash flow reveals that.
- Piotroski F-Score
- A balance-sheet health check developed by Joseph Piotroski: 9 yes/no criteria covering earnings, cash flow, leverage, and efficiency produce a score from 0 to 9. Scores of 7 or higher are considered financially very solid, scores under 3 a warning sign.
- Sector & Industry
- Two levels of industry classification: sector is broad (e.g., Technology), industry is narrow (e.g., Semiconductors). Many strategies watch industry strength, because strong stocks are almost always found in strong industries.
- Stage (Weinstein Stages 1-4)
- Stan Weinstein divides every price chart into four stages: Stage 1 = basing (sideways after a downtrend), Stage 2 = uptrend (the only buying stage), Stage 3 = topping, Stage 4 = downtrend (avoid, or short candidate). Measured against the 30-week line (150-day moving average) and its slope.
- Stress RS (Strength on Stress Days)
- A stress day is a day on which both the overall market and the stock's own sector fell at least 0.5%. Stress RS counts on how many of these days the stock still closed green (shown as "g/n" = green days out of n stress days) and turns that into a rating from 1 to 99. High values point to buyers stepping in even on weak days - often a sign of institutional accumulation.
Hit List
Filter ▾
Rating (traffic light)
Stage
Funda Rating
Piotroski
Columns ▾
This scanner's columns
Extra columns
Tip: clicking a column header sorts the table by that column; a second click flips the direction.
| Symbol | Earnings | Avg/Y 3Y | Stress RS | Stage | Funda Rating | Piotroski | MktCap | Industry | AI Rating | Deep Dive | Deep-Dive Report | Sector | Price | YTD | 6 Mo. | 1 Year | Off High | Price Target | RS | EPS Rating | ADR 10D | ADR 30D | Beta | P/E | P/E (f) | P/S | P/B | P/FCF | PEG | EV/EBITDA | EBIT Margin | Gross Margin | Net Margin | ROE | ROA | Debt/Eq | Equity Ratio | Sales +/Y | Growth Score | Div. Yield | Payout Ratio | Altman Z | Inst. % | Short % | Analysts |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIAV Viavi Solutions Inc | 08/06 | +127 % | 72 7/25 | Stage 2 | C 48 | 4 of 9 | 9.3 $ | Communication Equipment | Sells AI | — | — | Technology | 37.00 $ | +180.4 % | +159.6 % | +267.7 % | −16.5 % | +74.5 % | 98 | 9 | 8.6 % | 8.4 % | 1.19 | — | 29.6 | 6.8 | 10.8 | 203.9 | 1.34 | 82.0 | 12.2 % | 60.7 % | -4.0 % | -7.0 % | 3.6 % | 7.85 | 33.5 % | +8.4 % | — | 0.0 % | 0.0 % | -85.0 | 97.3 % | 6.8 % | 3.8 (9) |
| AIP Arteris Inc | 08/04 | +177 % | 61 6/25 | Stage 2 | C 48 | 3 of 9 | 1.4 $ | Semiconductors | Sells AI | — | — | Technology | 29.90 $ | +165.9 % | +197.1 % | +203.0 % | −3.8 % | +27.8 % | 98 | 42 | 7.1 % | 7.5 % | 1.92 | — | 0.0 | 18.4 | 501.5 | — | — | -7.7 | -38.0 % | 88.8 % | -44.9 % | -1,369.6 % | -17.9 % | 2.11 | 1.8 % | +22.3 % | — | 0.0 % | 0.0 % | -3.7 | 61.1 % | 7.3 % | 4.5 (4) |
| OTLK OUTLOOK THERAPEUTICS INC | 08/13 | -32 % | 71 6/22 | Stage 3 | D 29 | 4 of 9 | 0.1 $ | Biotechnology | Uses AI | — | Healthcare | 0.98 $ | +7.6 % | -7.7 % | -50.2 % | −52.5 % | +241.6 % | 97 | 42 | 16.8 % | 20.7 % | 0.78 | — | 2.8 | 483.3 | — | — | — | -4.1 | — | -360.8 % | 0.0 % | -3.7 % | -184.8 % | — | — | +730.9 % | — | 0.0 % | 0.0 % | -116.1 | 6.9 % | 10.1 % | — | |
| IBRX Immunitybio Inc | 08/04 | +57 % | 56 5/22 | Stage 2 | C 51 | 3 of 9 | 7.4 $ | Biotechnology | Uses AI | — | Healthcare | 7.20 $ | +269.7 % | +309.8 % | +191.5 % | −37.3 % | +77.1 % | 94 | 42 | 7.8 % | 7.0 % | 0.08 | — | 0.0 | 52.7 | — | — | — | -9.0 | -157.9 % | 99.3 % | 0.0 % | 0.0 % | -34.4 % | — | -134.5 % | +668.3 % | — | 0.0 % | 0.0 % | -23.1 | 17.6 % | 34.6 % | 4.6 (5) | |
| PGEN Precigen Inc | 08/11 | +125 % | 39 4/22 | Stage 2 | C 54 | 4 of 9 | 2.2 $ | Biotechnology | Neutral | — | — | Healthcare | 6.30 $ | +28.2 % | +41.3 % | +266.7 % | −2.8 % | +98.4 % | 93 | 42 | 6.5 % | 6.9 % | 1.01 | — | 312.5 | 70.9 | 117.8 | — | — | -3.3 | -25.8 % | -35.4 % | 0.0 % | -1,145.4 % | -42.1 % | 4.86 | 14.6 % | +146.7 % | — | 0.0 % | 0.0 % | -57.6 | 71.1 % | 21.2 % | 3.8 (4) |
| ARMP Armata Pharmaceuticals Inc | 08/11 | +51 % | 56 5/22 | Stage 1 | D 29 | 4 of 9 | 0.2 $ | Biotechnology | Neutral | — | — | Healthcare | 4.50 $ | +11.6 % | +0.8 % | +85.3 % | −60.2 % | +169.2 % | 91 | 42 | 11.0 % | 10.5 % | 1.27 | — | 0.0 | 31.3 | — | — | — | -3.5 | — | -215.2 % | 0.0 % | -3,439.4 % | -25.3 % | — | — | -5.2 % | — | 0.0 % | 0.0 % | -52.2 | 10.5 % | 1.9 % | — |
| CLPT Clearpoint Neuro Inc | 08/11 | +61 % | 40 4/22 | Stage 3 | D 44 | 4 of 9 | 0.5 $ | Medical Devices | Neutral | — | — | Healthcare | 14.90 $ | +35.5 % | +34.1 % | +43.7 % | −40.3 % | +90.2 % | 90 | 42 | 11.6 % | 9.0 % | 1.24 | — | 12.1 | 11.1 | 23.8 | — | 0.61 | -7.1 | — | 62.3 % | -71.6 % | -149.7 % | -25.0 % | 3.38 | — | +17.8 % | — | 0.0 % | 0.0 % | -3.1 | 50.6 % | 12.8 % | 5.0 (2) |
| KPTI Karyopharm Therapeutics Inc | 08/10 | -23 % | 94 9/22 | Stage 2 | D 38 | 4 of 9 | 0.0 $ | Biotechnology | Uses AI | — | — | Healthcare | 1.90 $ | +31.1 % | +35.0 % | -49.6 % | −13.9 % | +42.7 % | 89 | 42 | 7.7 % | 8.7 % | 0.81 | — | 0.0 | 0.3 | 2.4 | — | — | -1.9 | — | 13.5 % | -129.0 % | -891.1 % | -40.6 % | -0.87 | — | +0.6 % | — | 0.0 % | 0.0 % | -48.8 | 83.7 % | 24.8 % | — |
| CYTK Cytokinetics Inc | 08/06 | +8 % | 68 6/22 | Stage 2 | D 39 | 3 of 9 | 10.4 $ | Biotechnology | Neutral | — | Healthcare | 77.10 $ | +25.9 % | +36.0 % | +104.9 % | −2.6 % | +39.8 % | 88 | 42 | 4.6 % | 4.1 % | 0.42 | — | 117.6 | 97.8 | 57.5 | — | — | -15.8 | -948.7 % | -290.7 % | 0.0 % | -572.2 % | -31.5 % | -1.56 | -64.9 % | +376.6 % | — | 0.0 % | 0.0 % | -7.3 | 118.8 % | 19.4 % | 4.3 (21) | |
| MGTX MeiraGTx Holdings PLC | 08/13 | +23 % | 27 3/22 | Stage 2 | D 33 | 3 of 9 | 1.1 $ | Biotechnology | – | — | — | Healthcare | 11.80 $ | +48.6 % | +51.6 % | +54.1 % | −6.1 % | +148.2 % | 87 | 42 | 6.6 % | 5.8 % | 1.21 | — | 1.6 | 13.7 | 233.6 | — | — | -3.3 | — | 95.4 % | -151.1 % | -368.2 % | -28.1 % | -1.51 | — | +144.6 % | — | 0.0 % | 0.0 % | -13.6 | 60.9 % | 6.5 % | 4.6 (5) |
| ECOR Electrocore LLC | 08/05 | +35 % | 70 6/22 | Stage 2 | C 45 | 4 of 9 | 0.1 $ | Medical Devices | – | — | — | Healthcare | 6.10 $ | +86.2 % | +66.4 % | -12.1 % | −31.5 % | +166.6 % | 87 | 42 | 11.0 % | 11.5 % | 0.89 | — | 384.6 | 1.5 | 29.6 | — | — | 0.2 | — | 87.3 % | -44.1 % | -478.7 % | -58.1 % | -1.67 | — | +27.2 % | — | 0.0 % | 0.0 % | -44.7 | 9.2 % | 2.6 % | — |
| HURA TuHURA Biosciences Inc | 08/13 | -33 % | 82 7/22 | Stage 3 | E 19 | 3 of 9 | 0.1 $ | Biotechnology | Neutral | — | Healthcare | 2.20 $ | +248.7 % | +177.9 % | -12.5 % | −33.6 % | +210.4 % | 86 | 42 | 10.2 % | 9.0 % | — | — | 0.0 | — | — | — | — | 0.0 | — | — | 0.0 % | -187.2 % | -81.9 % | — | — | — | — | 0.0 % | 0.0 % | -16.0 | 15.0 % | 15.8 % | — | |
| BZFD BuzzFeed Inc | 08/06 | -20 % | 75 7/24 | Stage 3 | D 25 | 4 of 9 | 0.1 $ | Internet Content & Information | Threatened | — | — | Communication Services | 1.20 $ | +64.5 % | -12.4 % | -45.2 % | −50.0 % | -25.4 % | 86 | 13 | 10.5 % | 12.3 % | 3.77 | — | 172.4 | 0.5 | — | — | — | -7.7 | — | 40.3 % | -33.3 % | -90.2 % | -5.3 % | — | — | -2.4 % | — | 0.0 % | 0.0 % | -12.8 | 10.0 % | 3.2 % | — |
| ATRA Atara Biotherapeutics Inc | 08/10 | -29 % | 81 7/22 | Stage 3 | D 36 | 4 of 9 | 0.1 $ | Biotechnology | – | — | — | Healthcare | 8.40 $ | -38.3 % | -67.1 % | -27.3 % | −46.6 % | +33.7 % | 85 | 42 | 8.3 % | 8.3 % | 0.09 | — | 232.6 | 3.3 | 13.3 | — | — | 2.2 | — | 70.1 % | -40.9 % | -2,014.9 % | -3.8 % | -0.27 | — | -6.3 % | — | 0.0 % | 0.0 % | -327.5 | 52.5 % | 7.8 % | — |
| SHIM Shimmick Corporation Common Stock | 08/13 | — | 49 6/29 | Stage 1 | D 41 | 4 of 9 | 0.2 $ | Engineering & Construction | Neutral | — | — | Industrials | 3.80 $ | +25.3 % | +50.2 % | +113.6 % | −39.7 % | +83.8 % | 83 | 42 | 7.6 % | 8.4 % | 0.71 | — | 72.5 | 0.3 | 65.0 | — | — | 1,635.2 | — | 8.7 % | -4.4 % | -696.6 % | -4.3 % | -1.33 | — | +2.6 % | — | 0.0 % | 0.0 % | 0.3 | 8.7 % | 0.2 % | — |
| PLUG Plug Power Inc | 08/10 | -24 % | 66 8/29 | Stage 2 | D 43 | 3 of 9 | 2.9 $ | Electrical Equipment & Parts | – | — | — | Industrials | 2.10 $ | +37.6 % | +23.3 % | +37.3 % | −43.9 % | +68.9 % | 82 | 42 | 6.8 % | 8.2 % | 2.17 | — | 13.1 | 4.0 | 3.9 | — | 0.84 | -2.2 | -63.6 % | -31.2 % | -227.1 % | -128.8 % | -13.6 % | 1.35 | 31.7 % | +12.9 % | — | 0.0 % | 0.0 % | -10.6 | 68.9 % | 26.7 % | 3.2 (20) |
| IHRT iHeartMedia Inc Class A | 08/10 | +5 % | 50 5/24 | Stage 1 | D 26 | 4 of 9 | 0.5 $ | Broadcasting | – | — | — | Communication Services | 3.60 $ | -6.0 % | -0.4 % | +92.0 % | −37.4 % | +0.7 % | 81 | 89 | 7.6 % | 8.1 % | 2.20 | — | 51.3 | 0.1 | — | — | 5.03 | 19.1 | — | 58.6 % | -7.3 % | -2,444.0 % | 2.7 % | — | — | +0.3 % | — | 0.0 % | 0.0 % | 0.7 | 86.6 % | 7.4 % | 2.8 (4) |
| REAL TheRealReal Inc | 08/06 | +260 % | 21 4/31 | Stage 4 | C 54 | 3 of 9 | 1.5 $ | Luxury Goods | Uses AI | — | Consumer Cyclical | 12.10 $ | -22.6 % | -24.8 % | +129.9 % | −28.5 % | +42.6 % | 79 | 42 | 7.3 % | 6.4 % | 2.67 | — | 185.2 | 2.0 | 4.7 | 117.1 | — | 93.7 | -1.2 % | 74.5 % | -9.0 % | -932.7 % | -2.2 % | -1.29 | -93.1 % | +15.4 % | — | 0.0 % | 0.0 % | -9.2 | 98.4 % | 17.1 % | 3.6 (7) | |
| ACHV Achieve Life Sciences Inc | 08/06 | -5 % | 56 5/22 | Stage 2 | D 26 | 3 of 9 | 0.7 $ | Biotechnology | – | — | — | Healthcare | 6.40 $ | +0.8 % | +39.7 % | +146.0 % | −7.5 % | +115.6 % | 79 | 42 | 8.7 % | 8.2 % | 2.22 | — | 35.3 | — | — | — | 17.68 | -2.4 | — | — | 0.0 % | -496.2 % | -108.4 % | — | — | -100.0 % | — | 0.0 % | 0.0 % | -29.4 | 61.0 % | 14.4 % | 4.9 (8) |
| RDZN Roadzen Inc. | — | -31 % | 74 7/25 | Stage 1 | C 51 | 4 of 9 | 0.1 $ | Software - Application | Sells AI | — | — | Technology | 1.20 $ | -36.1 % | -24.9 % | -8.7 % | −43.4 % | +244.8 % | 79 | 42 | 9.6 % | 8.4 % | 1.20 | — | 0.0 | 2.0 | — | — | — | -4.4 | — | 61.3 % | -40.9 % | 0.0 % | -20.5 % | — | — | -5.2 % | — | 0.0 % | 0.0 % | -20.2 | 3.0 % | 1.2 % | — |
| BKSY Blacksky Technology Inc | 08/06 | +25 % | 99 15/29 | Stage 1 | D 31 | 2 of 9 | 0.9 $ | Specialty Business Services | Sells AI | — | — | Industrials | 23.10 $ | +43.5 % | +33.6 % | +19.8 % | −54.0 % | +75.3 % | 76 | 42 | 9.1 % | 10.7 % | 2.59 | — | 0.0 | 9.0 | — | — | — | 6.6 | — | 69.3 % | -89.1 % | -102.7 % | -10.6 % | — | — | +4.4 % | — | 0.0 % | 0.0 % | -2.1 | 68.4 % | 21.7 % | 5.0 (6) |
| ALLO Allogene Therapeutics Inc | 08/12 | -19 % | 16 2/22 | Stage 2 | D 33 | 2 of 9 | 0.7 $ | Biotechnology | – | — | — | Healthcare | 1.90 $ | +51.1 % | +58.6 % | +52.9 % | −53.8 % | +373.7 % | 75 | 42 | 6.7 % | 6.7 % | 0.46 | — | 0.0 | — | — | — | — | -1.0 | — | — | 0.0 % | -52.3 % | -26.0 % | — | — | -100.0 % | — | 0.0 % | 0.0 % | -10.0 | 53.3 % | 19.2 % | 4.4 (14) |
| NPCE Neuropace Inc | 08/11 | +85 % | — | Stage 2 | C 49 | 2 of 9 | 0.0 $ | Medical Devices | – | — | — | Healthcare | 12.90 $ | +3.1 % | +2.1 % | +51.5 % | −16.5 % | +22.2 % | 74 | 50 | 4.7 % | 4.7 % | 1.89 | — | 0.0 | — | 32.2 | — | — | -16.9 | — | 78.3 % | -21.7 % | -111.4 % | -10.0 % | 4.88 | — | +25.1 % | — | 0.0 % | 0.0 % | -11.4 | 96.3 % | 2.1 % | — |
| IMDX Insight Molecular Diagnostics Inc. | 08/10 | +11 % | 57 5/22 | Stage 4 | D 37 | 2 of 9 | 0.1 $ | Diagnostics & Research | Neutral | — | — | Healthcare | 4.70 $ | -28.4 % | -6.9 % | +84.5 % | −34.3 % | +49.1 % | 74 | 42 | 8.9 % | 10.6 % | 1.77 | — | 0.0 | 78.4 | 73.2 | — | — | -1.3 | — | 51.1 % | 0.0 % | -23,603.1 % | -43.4 % | -0.29 | — | +115.6 % | — | 0.0 % | 0.0 % | -34.6 | 61.4 % | 7.2 % | — |
| CDXS Codexis Inc | 08/12 | -5 % | 16 2/22 | Stage 2 | C 49 | 4 of 9 | 0.1 $ | Biotechnology | – | — | — | Healthcare | 1.40 $ | +46.6 % | +38.7 % | -47.8 % | −41.9 % | +192.6 % | 73 | 42 | 6.9 % | 6.5 % | 2.50 | — | 149.3 | 1.7 | — | — | 13.53 | -10.7 | — | 23.8 % | -41.0 % | -68.9 % | -12.5 % | — | — | +18.6 % | — | 0.0 % | 0.0 % | -10.0 | 74.4 % | 3.6 % | — |
| EBC Eastern Bankshares Inc | 07/23 | +33 % | 1 0/22 | Stage 2 | C 52 | 4 of 9 | 4.9 $ | Banks - Regional | – | — | — | Financial Services | 23.00 $ | +15.5 % | +19.3 % | +53.0 % | −3.2 % | +9.2 % | 64 | 78 | 2.3 % | 2.3 % | 0.68 | 12.8 | 12.3 | 3.5 | 1.2 | 13.8 | — | 0.0 | 45.9 % | 100.0 % | 34.3 % | 9.4 % | 1.3 % | 0.22 | 14.0 % | -1.2 % | — | 2.4 % | 31.8 % | -1.5 | 81.3 % | 8.4 % | 4.0 (4) |
| FMBH First Mid Illinois Bancshares Inc | 07/23 | +34 % | 2 0/22 | Stage 2 | C 53 | 4 of 9 | 1.4 $ | Banks - Regional | – | — | — | Financial Services | 52.10 $ | +21.9 % | +20.7 % | +40.7 % | −3.2 % | +8.4 % | 64 | 61 | 2.8 % | 2.5 % | 0.79 | — | 12.0 | 3.0 | — | 13.7 | 1.27 | 0.0 | 40.5 % | 100.0 % | 26.9 % | 9.9 % | 1.2 % | — | 11.6 % | +4.2 % | — | 2.0 % | 23.0 % | -1.4 | 53.6 % | 2.1 % | 3.9 (7) |
| BBIO BridgeBio Pharma Inc | 08/04 | +113 % | 68 6/22 | Stage 1 | C 54 | 3 of 9 | 15.7 $ | Biotechnology | – | — | — | Healthcare | 80.10 $ | -10.3 % | -5.9 % | +69.4 % | −18.0 % | +31.4 % | 59 | 42 | 3.7 % | 4.0 % | 0.95 | — | 0.0 | 27.0 | 142.2 | — | — | -9.4 | -54.5 % | 95.1 % | -124.4 % | -1,789.7 % | -28.0 % | -1.49 | -165.5 % | +126.3 % | — | 0.0 % | 0.0 % | -7.9 | 103.2 % | 14.7 % | 4.4 (19) |
| AQST Aquestive Therapeutics Inc | 08/10 | +58 % | 28 3/22 | Stage 3 | C 47 | 3 of 9 | 0.5 $ | Drug Manufacturers - Specialty & Generic | – | — | — | Healthcare | 3.70 $ | -22.1 % | -30.3 % | -3.8 % | −40.9 % | +140.2 % | 59 | 42 | 6.5 % | 5.1 % | 1.45 | — | 0.0 | 9.2 | 11.7 | — | — | -1.8 | — | 63.4 % | -137.1 % | 0.0 % | -28.7 % | -3.92 | — | -22.6 % | — | 0.0 % | 0.0 % | -5.4 | 60.6 % | 13.9 % | 4.6 (9) |
| BIRD Allbirds Inc | 08/06 | -32 % | 21 4/31 | Stage 3 | E 17 | 3 of 9 | 0.0 $ | Apparel Retail | – | — | — | Consumer Cyclical | 2.20 $ | +24.9 % | -84.6 % | -78.0 % | −82.4 % | +227.1 % | 57 | 42 | 23.0 % | 13.8 % | 2.56 | — | 0.0 | 0.2 | 1.4 | — | — | -0.6 | — | 38.1 % | -53.4 % | -153.7 % | -38.8 % | 2.04 | — | -19.7 % | — | 0.0 % | 0.0 % | -23.1 | 35.4 % | 16.9 % | — |
| W Wayfair Inc | 08/03 | +16 % | 8 2/31 | Stage 4 | D 42 | 3 of 9 | 11.2 $ | Internet Retail | – | — | — | Consumer Cyclical | 84.90 $ | -15.5 % | -5.0 % | +29.3 % | −22.1 % | +12.7 % | 56 | 13 | 6.5 % | 6.8 % | 2.96 | — | 30.7 | 0.9 | 2,432.5 | 24.6 | 23.50 | 107.7 | 0.4 % | 30.4 % | -2.4 % | 0.0 % | 3.7 % | -1.28 | -99.0 % | +5.1 % | — | 0.0 % | 0.0 % | -4.4 | 113.3 % | 18.1 % | 3.8 (35) |
| EDIT Editas Medicine Inc | 08/11 | -27 % | 29 3/22 | Stage 3 | D 42 | 2 of 9 | 0.4 $ | Biotechnology | Neutral | — | Healthcare | 2.60 $ | +27.8 % | +27.2 % | +2.8 % | −36.9 % | +130.8 % | 54 | 42 | 8.7 % | 10.1 % | 2.10 | — | 0.0 | 10.3 | 92.6 | — | — | -1.4 | -883.2 % | -109.2 % | -281.6 % | -326.1 % | -27.0 % | 0.40 | 14.6 % | +25.4 % | — | 0.0 % | 0.0 % | -11.5 | 49.4 % | 14.5 % | 3.5 (15) | |
| MNKD MannKind Corp | 08/05 | +0 % | 69 6/22 | Stage 4 | D 38 | 2 of 9 | 1.2 $ | Biotechnology | Uses AI | — | Healthcare | 3.90 $ | -30.7 % | -28.5 % | +3.4 % | −39.6 % | +97.9 % | 53 | 19 | 5.3 % | 5.9 % | 1.09 | — | 41.3 | 3.3 | 186.4 | 93.8 | 4.39 | 51.0 | -3.3 % | 75.6 % | -6.6 % | 0.0 % | 2.0 % | -7.38 | -8.0 % | +22.2 % | — | 0.0 % | 0.0 % | -9.8 | 59.3 % | 9.3 % | 4.9 (7) | |
| EOLS Evolus Inc | 08/04 | -5 % | 40 4/22 | Stage 3 | C 46 | 4 of 9 | 0.4 $ | Drug Manufacturers - Specialty & Generic | – | — | — | Healthcare | 5.80 $ | +1.4 % | +4.1 % | -34.5 % | −29.9 % | +152.9 % | 52 | 42 | 4.7 % | 4.9 % | 1.32 | — | 53.2 | 1.3 | — | — | — | -21.5 | — | 66.1 % | -14.4 % | -18,729.6 % | -9.1 % | — | — | +11.6 % | — | 0.0 % | 0.0 % | -5.4 | 70.1 % | 9.1 % | 4.6 (7) |
| OBIO Orchestra BioMed Holdings Inc. | 08/11 | -17 % | 7 1/22 | Stage 1 | D 39 | 3 of 9 | 0.2 $ | Biotechnology | – | — | — | Healthcare | 4.00 $ | -2.7 % | +9.7 % | +30.1 % | −28.1 % | +212.0 % | 52 | 42 | 6.7 % | 5.4 % | 0.48 | — | 0.0 | 7.3 | 6.3 | — | — | -1.8 | — | 99.5 % | -167.0 % | -161.1 % | -43.0 % | 0.66 | — | +1,169.2 % | — | 0.0 % | 0.0 % | -6.3 | 41.7 % | 3.4 % | — |
| GEG Great Elm Group Inc | 09/01 | +6 % | 70 6/22 | Stage 3 | E 24 | 4 of 9 | 0.1 $ | Asset Management | – | — | — | Financial Services | 2.20 $ | -4.3 % | -7.8 % | +4.4 % | −35.9 % | +722.2 % | 50 | 53 | 11.0 % | 6.2 % | 0.57 | — | 42.7 | 2.8 | 1.7 | 5.6 | 0.77 | 0.4 | — | -16.5 % | -100.5 % | -42.3 % | -6.7 % | 1.59 | — | -8.5 % | — | 48.8 % | 0.0 % | -87.5 | 40.1 % | 3.8 % | — |
| UBCP United Bancorp Inc | 07/30 | +21 % | 97 10/22 | Stage 2 | C 53 | 4 of 9 | 0.1 $ | Banks - Regional | – | — | — | Financial Services | 15.30 $ | +13.4 % | +13.9 % | +15.4 % | −9.1 % | +26.8 % | 49 | 53 | 3.3 % | 3.1 % | 0.36 | 11.7 | 10.3 | 1.8 | 1.3 | 18.0 | — | 0.0 | — | 100.0 % | 24.1 % | 12.2 % | 0.9 % | 1.74 | — | +8.0 % | — | 4.7 % | 68.8 % | -0.7 | 13.5 % | 0.2 % | — |
| RARE Ultragenyx | 08/04 | -14 % | 69 6/22 | Stage 3 | D 37 | 0 of 9 | 2.5 $ | Biotechnology | – | — | — | Healthcare | 24.90 $ | +25.0 % | -11.3 % | -8.8 % | −31.0 % | +114.3 % | 48 | 42 | 5.5 % | 5.2 % | 0.31 | — | 0.0 | 3.7 | — | — | — | -6.5 | -102.2 % | -28.1 % | -90.9 % | -608.5 % | -25.5 % | — | -18.2 % | +20.1 % | — | 0.0 % | 0.0 % | -9.9 | 104.2 % | 14.1 % | 4.6 (20) |
| OSTX OS Therapies Incorporated | 08/17 | — | 82 7/22 | Stage 3 | D 27 | 2 of 9 | 0.1 $ | Biotechnology | – | — | — | Healthcare | 1.50 $ | +30.0 % | +47.4 % | -14.6 % | −30.0 % | +422.1 % | 45 | 42 | 8.5 % | 8.3 % | — | — | 1.7 | — | 11.4 | — | — | 0.0 | — | — | 0.0 % | -914.0 % | -366.6 % | -0.12 | — | — | — | 0.0 % | 0.0 % | -78.9 | 6.5 % | 4.9 % | — |
| TCBX Third Coast Bancshares, Inc. | 07/22 | +45 % | — | Stage 3 | C 50 | 4 of 9 | 0.0 $ | Banks - Regional | – | — | — | Financial Services | 43.80 $ | +4.9 % | +1.1 % | +16.4 % | −8.0 % | +5.9 % | 44 | 50 | 2.5 % | 2.4 % | 0.65 | 10.8 | 10.4 | — | 1.1 | — | — | 0.0 | — | 100.0 % | 32.4 % | 12.2 % | 1.2 % | 0.24 | — | +8.5 % | — | 0.0 % | 0.0 % | -1.5 | 57.0 % | 3.0 % | — |
| SPCE Virgin Galactic Holdings Inc | 08/05 | -32 % | 18 3/29 | Stage 1 | D 40 | 3 of 9 | 0.3 $ | Aerospace & Defense | Neutral | — | Industrials | 2.60 $ | -6.5 % | -12.0 % | -32.9 % | −71.9 % | +42.0 % | 43 | 42 | 11.4 % | 18.9 % | 2.74 | — | 0.0 | 220.0 | — | — | — | -0.1 | — | -6,127.7 % | 0.0 % | -104.5 % | -19.8 % | — | — | -78.1 % | — | 0.0 % | 0.0 % | -10.8 | 15.8 % | 32.4 % | — | |
| CNVS Cineverse Corp. | 08/13 | +12 % | 84 8/24 | Stage 3 | D 34 | 1 of 9 | 0.1 $ | Entertainment | – | — | — | Communication Services | 2.40 $ | +35.1 % | +34.0 % | -52.4 % | −63.7 % | +291.8 % | 43 | 42 | 10.7 % | 7.1 % | 1.52 | — | 38.8 | 0.9 | — | — | 0.46 | 10.1 | — | 53.4 % | -13.4 % | -24.5 % | -9.3 % | — | — | +59.1 % | — | 0.0 % | 0.0 % | -20.6 | 16.5 % | 2.7 % | — |
| BCRX BioCryst Pharmaceuticals Inc | 08/03 | +11 % | 80 7/22 | Stage 2 | D 42 | 2 of 9 | 2.3 $ | Drug Manufacturers - Specialty & Generic | – | — | — | Healthcare | 9.00 $ | +19.4 % | +24.0 % | +10.3 % | −9.5 % | +133.3 % | 42 | 42 | 5.9 % | 4.7 % | 0.54 | — | 87.0 | 2.6 | 51.4 | 7.7 | 9.39 | 7.2 | -2.5 % | 76.6 % | -51.7 % | -1,925.4 % | 42.6 % | -1.55 | -119.1 % | +94.1 % | — | 0.0 % | 0.0 % | -15.9 | 101.1 % | 12.4 % | 4.4 (12) |
| ELUT Elutia Inc. | 08/13 | -20 % | 93 9/22 | Stage 2 | D 32 | 3 of 9 | 0.0 $ | Medical Devices | – | — | — | Healthcare | 0.86 $ | +48.7 % | +71.0 % | -57.8 % | −64.1 % | +426.3 % | 41 | 42 | 7.1 % | 8.1 % | 0.85 | — | 0.0 | 2.7 | 1.8 | — | — | -3.3 | — | 56.3 % | 400.2 % | 0.0 % | -26.4 % | 0.52 | — | -49.6 % | — | 0.0 % | 0.0 % | -7.2 | 45.7 % | 0.1 % | — |
| NG NovaGold Resources Inc | — | +19 % | 11 2/23 | Stage 4 | D 29 | 4 of 9 | 2.5 $ | Gold | – | — | — | Basic Materials | 5.80 $ | -22.5 % | -39.5 % | +12.3 % | −57.3 % | +139.8 % | 40 | 42 | 8.2 % | 6.7 % | 2.15 | — | 4.9 | — | — | — | 1.34 | -40.4 | 0.0 % | — | 0.0 % | -52.0 % | -4.4 % | — | 70.3 % | -100.0 % | — | 0.0 % | 0.0 % | -2.2 | 79.3 % | 8.3 % | 4.4 (8) |
| BETR Better Home & Finance Holding Company | 08/12 | -33 % | — | Stage 4 | D 42 | 3 of 9 | 0.0 $ | Mortgage Finance | – | — | — | Financial Services | 23.50 $ | -21.1 % | -28.2 % | +81.6 % | −72.8 % | +61.1 % | 40 | 50 | 9.0 % | 8.7 % | 1.73 | — | 0.0 | — | — | — | — | -0.9 | — | 100.0 % | -102.5 % | -875.5 % | -13.2 % | — | — | +59.4 % | — | 0.0 % | 0.0 % | -1.0 | 46.6 % | 23.1 % | — |
| GRPN Groupon Inc | 08/05 | +68 % | 84 8/24 | Stage 3 | D 36 | 3 of 9 | 1.1 $ | Internet Content & Information | Uses AI | — | Communication Services | 27.60 $ | -4.8 % | +29.9 % | -10.6 % | −46.9 % | -4.6 % | 38 | 86 | 9.3 % | 8.9 % | 0.22 | — | 153.8 | 2.1 | 21.4 | 26.3 | 14.66 | 17.4 | — | 90.7 % | -20.8 % | -15.2 % | 0.8 % | -5.02 | — | +1.2 % | — | 0.0 % | 0.0 % | -7.0 | 148.1 % | 59.9 % | 4.0 (4) | |
| SABR Sabre Corporation | 08/06 | -15 % | 73 7/25 | Stage 3 | C 46 | 4 of 9 | 0.8 $ | Software - Infrastructure | Sells AI | — | Technology | 1.90 $ | +28.7 % | +47.2 % | -38.9 % | −46.9 % | +4.7 % | 36 | 6 | 9.0 % | 7.4 % | 0.96 | — | 37.7 | 0.3 | 147.4 | — | 1.68 | 12.7 | — | 56.5 % | 17.6 % | -737.4 % | 5.1 % | -4.10 | — | -8.5 % | — | 0.0 % | 0.0 % | 0.0 | 90.2 % | 11.0 % | 3.7 (7) | |
| NN Nextnav Acquisition Corp | 08/05 | +156 % | 95 11/25 | Stage 1 | E 21 | 3 of 9 | 1.8 $ | Software - Infrastructure | Neutral | — | — | Technology | 13.10 $ | +2.9 % | +4.6 % | -11.4 % | −31.7 % | +157.0 % | 35 | 42 | 7.7 % | 8.5 % | 1.07 | — | 0.0 | 445.5 | 187.7 | — | — | -1.6 | -1,913.9 % | -101.8 % | 0.0 % | -706.8 % | -17.3 % | -3.13 | -38.2 % | -19.3 % | — | 0.0 % | 0.0 % | -11.9 | 71.0 % | 15.9 % | 4.0 (2) |
| ELWT Elauwit Connection, Inc. Common Stock | 08/13 | — | 94 10/24 | Stage 1 | D 36 | 3 of 9 | 0.1 $ | Telecom Services | – | — | — | Communication Services | 8.20 $ | +18.9 % | +30.7 % | — | −36.8 % | +95.4 % | 31 | 42 | 10.5 % | 10.2 % | — | — | 0.0 | 2.6 | 23.9 | — | — | 0.0 | — | 17.3 % | -28.9 % | 0.0 % | -35.6 % | 0.82 | — | +154.5 % | — | 0.0 % | 0.0 % | -4.6 | 8.6 % | 1.1 % | — |
| CDZI Cadiz Inc | 08/12 | +1 % | 50 3/15 | Stage 4 | D 39 | 3 of 9 | 0.3 $ | Utilities - Regulated Water | – | — | — | Utilities | 3.00 $ | -27.5 % | -32.0 % | -6.0 % | −47.6 % | +219.6 % | 29 | 42 | 6.6 % | 6.7 % | 1.83 | — | 14.9 | 16.8 | — | — | 1.51 | -25.1 | — | 31.4 % | -221.4 % | -111.3 % | -10.7 % | — | — | +69.8 % | — | 0.0 % | 0.0 % | -12.9 | 48.8 % | 12.5 % | — |
| GROV Grove Collaborative Holdings, Inc. | 08/06 | -9 % | 65 4/16 | Stage 4 | C 45 | 4 of 9 | 0.0 $ | Household & Personal Products | – | — | — | Consumer Defensive | 1.10 $ | +10.9 % | +9.4 % | -21.4 % | −32.1 % | +60.0 % | 28 | 42 | 5.6 % | 6.3 % | 1.04 | — | 0.1 | 0.3 | — | — | — | -3.4 | — | 54.1 % | -5.5 % | -89.6 % | -9.8 % | — | — | -14.6 % | — | 0.0 % | 0.0 % | -38.9 | 30.4 % | 9.3 % | — |
| PACB Pacific Biosciences of California | 08/06 | -30 % | 15 2/22 | Stage 4 | D 32 | 3 of 9 | 0.4 $ | Medical Devices | – | — | — | Healthcare | 1.40 $ | -29.9 % | -8.0 % | +1.5 % | −41.4 % | +75.6 % | 26 | 42 | 8.6 % | 8.4 % | 2.29 | — | 0.0 | 2.7 | 189.5 | — | — | 140.8 | — | 38.3 % | -80.4 % | -273.6 % | -12.0 % | 297.29 | — | +3.9 % | — | 0.0 % | 0.0 % | -6.5 | 54.0 % | 17.1 % | 3.8 (14) |
| MDAI Spectral AI Inc. | 08/11 | -28 % | 70 6/22 | Stage 3 | D 27 | 1 of 9 | 0.0 $ | Medical Devices | – | — | — | Healthcare | 1.60 $ | +20.4 % | +17.4 % | -37.5 % | −48.0 % | +224.4 % | 26 | 42 | 4.9 % | 7.9 % | 1.17 | — | 52.4 | 2.8 | — | — | — | -3.4 | — | 46.0 % | -82.0 % | -2,308.3 % | -31.5 % | — | — | -33.6 % | — | 0.0 % | 0.0 % | -14.9 | 15.2 % | 10.5 % | — |
| OM Outset Medical Inc | 08/05 | -33 % | 7 1/22 | Stage 3 | D 37 | 4 of 9 | 0.1 $ | Medical Devices | – | — | — | Healthcare | 4.60 $ | +28.3 % | +31.6 % | -71.5 % | −78.5 % | +67.0 % | 24 | 42 | 11.0 % | 9.7 % | 1.94 | — | 0.0 | 0.7 | — | — | — | -0.2 | — | 40.6 % | -63.7 % | -53.2 % | -15.3 % | — | — | +5.1 % | — | 0.0 % | 0.0 % | -7.8 | 84.2 % | 14.5 % | — |
| FTCI FTC Solar Inc | 08/04 | -30 % | 62 6/25 | Stage 4 | C 53 | 4 of 9 | 0.0 $ | Solar | – | — | — | Technology | 2.80 $ | -52.2 % | -58.7 % | -51.8 % | −64.2 % | +124.8 % | 22 | 42 | 9.6 % | 9.9 % | 1.81 | — | 18.8 | 0.4 | 7.5 | — | — | -0.7 | — | 1.4 % | -44.9 % | -955.8 % | -25.3 % | -3.81 | — | +110.5 % | — | 0.0 % | 0.0 % | -10.6 | 10.1 % | 9.0 % | — |
| BKKT Bakkt Holdings Inc | 08/10 | -30 % | 20 3/25 | Stage 4 | E 19 | 3 of 9 | 0.3 $ | Software - Infrastructure | – | — | — | Technology | 7.20 $ | -11.7 % | -23.3 % | -27.6 % | −84.3 % | +142.7 % | 20 | 42 | 9.7 % | 10.7 % | 5.90 | — | 0.0 | 0.2 | 2.0 | — | — | 0.8 | — | -6.9 % | -8.4 % | -102.0 % | -37.4 % | 0.00 | — | -33.1 % | — | 0.0 % | 0.0 % | -7.7 | 21.4 % | 25.0 % | — |
| TVGN Tevogen Bio Holdings Inc. | 08/18 | -33 % | 58 5/22 | Stage 4 | E 19 | 4 of 9 | 0.0 $ | Biotechnology | – | — | — | Healthcare | 7.10 $ | -42.5 % | -68.2 % | -85.7 % | −20.7 % | -79.0 % | 20 | 42 | 12.9 % | 16.1 % | 0.22 | — | 0.0 | — | 0.0 | — | — | 18.3 | — | — | 0.0 % | 0.0 % | -294.4 % | -0.31 | — | — | — | 0.0 % | 0.0 % | -129.5 | 3.6 % | 5.3 % | — |
| EVLV Evolv Technologies Holdings Inc | 08/13 | -2 % | 85 10/29 | Stage 4 | C 47 | 3 of 9 | 1.0 $ | Security & Protection Services | – | — | — | Industrials | 5.50 $ | -22.6 % | -15.8 % | -15.6 % | −41.3 % | +84.1 % | 19 | 42 | 4.8 % | 4.8 % | 1.77 | — | 43.3 | 6.2 | 8.6 | — | — | -5.1 | — | 49.8 % | -22.8 % | -30.2 % | -5.8 % | 0.35 | — | +40.5 % | — | 0.0 % | 0.0 % | -0.5 | 72.9 % | 5.2 % | 4.5 (4) |
| SERA Sera Prognostics Inc | 08/05 | -31 % | 58 5/22 | Stage 4 | D 32 | 2 of 9 | 0.1 $ | Medical Devices | – | — | — | Healthcare | 2.00 $ | -37.6 % | -49.7 % | -26.6 % | −56.0 % | +205.6 % | 15 | 42 | 6.5 % | 9.2 % | 0.97 | — | 0.0 | — | 1.2 | — | — | -0.6 | — | -191.2 % | 0.0 % | -39.6 % | -21.6 % | 0.04 | — | +5.2 % | — | 0.0 % | 0.0 % | -5.6 | 63.1 % | 0.9 % | — |
| OWLT Owlet Inc | 08/06 | +3 % | 16 2/22 | Stage 4 | D 40 | 3 of 9 | 0.1 $ | Medical Devices | – | — | — | Healthcare | 5.20 $ | -67.4 % | -62.5 % | -29.6 % | −68.5 % | +143.4 % | 12 | 42 | 9.0 % | 7.4 % | 1.84 | — | 0.0 | 1.4 | — | — | — | -0.6 | — | 50.9 % | -43.0 % | -526.2 % | -10.0 % | — | — | +35.4 % | — | 0.0 % | 0.0 % | -8.5 | 74.4 % | 2.4 % | — |
| COCH Envoy Medical Inc. | 07/30 | -33 % | 93 9/22 | Stage 4 | D 27 | 4 of 9 | 0.1 $ | Medical Devices | – | — | — | Healthcare | 0.67 $ | -1.7 % | -8.8 % | -54.0 % | −64.4 % | +273.1 % | 11 | 42 | 10.6 % | 7.5 % | 1.86 | — | 0.0 | 260.0 | — | — | — | -1.4 | — | -229.5 % | 0.0 % | 0.0 % | -71.3 % | — | — | +7.1 % | — | 0.0 % | 0.0 % | -32.6 | 22.9 % | 2.5 % | — |
| LUNG Pulmonx Corp | 07/29 | -30 % | — | Stage 4 | D 34 | 3 of 9 | 0.0 $ | Medical Devices | – | — | — | Healthcare | 1.60 $ | -42.1 % | -41.7 % | -11.4 % | −67.8 % | +172.0 % | 10 | 50 | 8.4 % | 7.8 % | 0.31 | — | 28.3 | — | — | — | — | -5.6 | — | 75.5 % | -60.1 % | -86.2 % | -24.0 % | — | — | +8.0 % | — | 0.0 % | 0.0 % | -9.4 | 79.1 % | 6.4 % | — |
| AEYE AudioEye Inc | 08/06 | +3 % | 20 3/25 | Stage 4 | D 41 | 4 of 9 | 0.1 $ | Software - Application | – | — | — | Technology | 5.80 $ | -40.1 % | -47.6 % | -54.8 % | −63.5 % | +163.4 % | 10 | 42 | 7.2 % | 6.7 % | 0.82 | — | 7.0 | 1.6 | 23.4 | 11.4 | 2.16 | 567.8 | — | 78.0 % | -9.0 % | -66.9 % | -7.6 % | 5.33 | — | +14.5 % | — | 0.0 % | 0.0 % | -7.1 | 36.5 % | 5.7 % | — |
| TELA Tela Bio Inc | 08/10 | -31 % | 94 9/22 | Stage 4 | D 35 | 4 of 9 | 0.0 $ | Medical Devices | – | — | — | Healthcare | 0.73 $ | -33.4 % | -35.9 % | -57.1 % | −66.4 % | +204.1 % | 10 | 42 | 12.2 % | 11.7 % | 1.34 | — | 0.0 | 0.5 | 7.2 | — | — | -5.0 | — | 67.7 % | -49.3 % | -616.6 % | -28.7 % | -10.84 | — | +15.8 % | — | 0.0 % | 0.0 % | -14.8 | 69.0 % | 1.0 % | — |
| VSTM Verastem Inc | 08/06 | -17 % | 40 4/22 | Stage 4 | D 35 | 3 of 9 | 0.5 $ | Biotechnology | – | — | — | Healthcare | 5.80 $ | -45.5 % | -51.5 % | -6.0 % | −69.3 % | +158.6 % | 9 | 42 | 8.6 % | 7.4 % | 0.29 | — | 0.0 | 10.3 | 6.8 | — | — | -0.2 | — | 85.1 % | 0.0 % | -786.2 % | -59.4 % | 1.05 | — | +209.1 % | — | 0.0 % | 0.0 % | -15.1 | 93.6 % | 23.0 % | 4.8 (9) |
| CVRX CVRx Inc | 08/03 | -21 % | 89 8/22 | Stage 4 | D 37 | 3 of 9 | 0.1 $ | Medical Devices | – | — | — | Healthcare | 5.20 $ | -27.5 % | -22.7 % | -35.0 % | −53.5 % | +112.7 % | 9 | 42 | 6.8 % | 7.0 % | 0.78 | — | 0.0 | 2.4 | — | — | — | -1.3 | — | 86.2 % | -89.1 % | -107.0 % | -27.3 % | — | — | +10.5 % | — | 0.0 % | 0.0 % | -13.5 | 63.6 % | 9.3 % | — |
| CRGO Freightos Limited Ordinary shares | 08/17 | -20 % | 60 7/29 | Stage 4 | C 53 | 3 of 9 | 0.1 $ | Integrated Freight & Logistics | – | — | — | Industrials | 1.20 $ | -36.8 % | -40.7 % | -58.9 % | −67.9 % | +105.9 % | 9 | 42 | 6.7 % | 7.6 % | 1.16 | — | 0.0 | 2.0 | 1.7 | — | — | -1.1 | — | 66.8 % | -65.6 % | -43.8 % | -18.4 % | 0.06 | — | +23.9 % | — | 0.0 % | 0.0 % | -8.5 | 26.0 % | 0.6 % | — |
| WGS GeneDx Holdings Corp. | 08/04 | +283 % | 39 4/22 | Stage 4 | D 40 | 2 of 9 | 1.9 $ | Diagnostics & Research | – | — | — | Healthcare | 65.10 $ | -55.3 % | -49.2 % | -36.1 % | −59.8 % | +25.6 % | 8 | 42 | 7.9 % | 8.0 % | 1.91 | — | 204.1 | 4.2 | 7.7 | — | — | 161.2 | — | 69.6 % | -17.6 % | -30.4 % | -4.4 % | 0.66 | — | +40.0 % | — | 0.0 % | 0.0 % | -3.6 | 114.7 % | 37.8 % | 4.7 (6) |
| ALDX Aldeyra Therapeutics, Inc. | 08/06 | -24 % | 70 6/22 | Stage 4 | C 47 | 1 of 9 | 0.1 $ | Biotechnology | – | — | — | Healthcare | 1.50 $ | -61.0 % | -61.2 % | -69.1 % | −70.9 % | +322.2 % | 8 | 42 | 9.5 % | 8.5 % | 1.15 | — | 0.0 | — | 2.1 | — | — | 7.0 | — | — | 0.0 % | -51.8 % | -22.2 % | 0.37 | — | — | — | 0.0 % | 0.0 % | -17.3 | 62.8 % | 11.8 % | — |
| RMTI Rockwell Medical Inc | 08/13 | -28 % | 58 5/22 | Stage 4 | D 26 | 4 of 9 | 0.0 $ | Drug Manufacturers - Specialty & Generic | – | — | — | Healthcare | 7.20 $ | -19.9 % | -27.4 % | -22.7 % | −69.0 % | +4,515.4 % | 8 | 42 | 6.4 % | 5.9 % | 1.62 | — | 33.0 | 0.5 | 0.8 | 18.3 | 4.43 | 22.1 | — | 17.1 % | -8.0 % | -16.0 % | -5.4 % | 0.40 | — | -31.8 % | — | 0.0 % | 0.0 % | -15.4 | 10.1 % | 1.9 % | — |
| AUID authID Inc. | 08/13 | -27 % | 73 7/25 | Stage 4 | C 45 | 4 of 9 | 0.0 $ | Software - Infrastructure | – | — | — | Technology | 0.73 $ | +17.8 % | +2.9 % | -81.5 % | −82.3 % | — | 6 | 42 | 6.7 % | 8.5 % | 1.57 | — | 0.0 | 5.9 | — | — | — | -0.5 | — | 100.0 % | 0.0 % | -281.5 % | -139.0 % | — | — | +130.2 % | — | 0.0 % | 0.0 % | -109.6 | 13.6 % | 6.2 % | — |
| TIL Instil Bio Inc. | 08/12 | -20 % | 89 8/22 | Stage 4 | D 29 | 4 of 9 | 0.0 $ | Biotechnology | Neutral | — | — | Healthcare | 7.10 $ | -31.3 % | -34.3 % | -70.3 % | −78.0 % | -6.2 % | 6 | 42 | 4.3 % | 2.9 % | 1.91 | — | 0.0 | — | 0.4 | — | — | 0.6 | — | — | 0.0 % | -37.1 % | -12.7 % | 0.77 | — | -100.0 % | — | 0.0 % | 0.0 % | -2.7 | 62.2 % | 5.8 % | — |
| AKBA Akebia Therapeutics, Inc. | 08/06 | +3 % | 29 3/22 | Stage 4 | D 32 | 1 of 9 | 0.3 $ | Drug Manufacturers - Specialty & Generic | – | — | — | Healthcare | 1.30 $ | -31.7 % | -34.7 % | -64.2 % | −74.5 % | +223.1 % | 5 | 42 | 7.0 % | 7.4 % | 0.24 | — | 28.7 | 1.5 | 14.0 | 5.7 | — | 66.9 | — | 81.9 % | -8.8 % | -79.0 % | 2.0 % | 0.46 | — | +47.5 % | — | 0.0 % | 0.0 % | -10.8 | 42.1 % | 7.2 % | 4.8 (4) |
| HUMA Humacyte Inc | 08/10 | -26 % | 16 2/22 | Stage 4 | D 34 | 2 of 9 | 0.2 $ | Biotechnology | – | — | — | Healthcare | 0.65 $ | -27.1 % | -26.0 % | -72.8 % | −78.2 % | +230.6 % | 5 | 42 | 14.9 % | 12.7 % | 2.52 | — | 35.8 | 84.3 | 17.0 | — | — | 4.3 | — | -4,053.7 % | 0.0 % | -409.5 % | -51.5 % | 5.67 | — | -100.0 % | — | 0.0 % | 0.0 % | -21.1 | 22.3 % | 13.7 % | — |
| BYND Beyond Meat Inc | 08/05 | -33 % | 28 2/16 | Stage 4 | D 26 | 4 of 9 | 0.3 $ | Packaged Foods | – | — | — | Consumer Defensive | 0.57 $ | -17.3 % | -28.2 % | -81.4 % | −91.1 % | +2.9 % | 5 | 42 | 6.9 % | 6.9 % | 2.75 | — | 5,000.0 | 1.1 | 49.4 | — | 40.75 | 2.2 | — | 10.8 % | 95.0 % | -1,167.0 % | -17.0 % | -23.58 | — | -15.6 % | — | 0.0 % | 0.0 % | -4.6 | 38.1 % | 28.9 % | — |
| RPID Rapid Micro Biosystems Inc | 08/11 | +24 % | 30 3/22 | Stage 4 | D 37 | 2 of 9 | 0.1 $ | Medical Devices | – | — | — | Healthcare | 2.10 $ | -41.7 % | -44.2 % | -36.0 % | −65.6 % | +292.2 % | 5 | 42 | 4.3 % | 6.4 % | 1.47 | — | 0.0 | 3.3 | — | — | — | 0.8 | — | 2.9 % | -145.8 % | -116.7 % | -41.9 % | — | — | +19.7 % | — | 0.0 % | 0.0 % | -26.3 | 54.1 % | 2.0 % | — |
| SRFM Surf Air Mobility Inc. | 08/11 | — | 9 2/29 | Stage 4 | D 32 | 4 of 9 | 0.1 $ | Airlines | – | — | — | Industrials | 0.76 $ | -45.9 % | -56.3 % | -81.7 % | −90.8 % | +483.8 % | 5 | 42 | 12.5 % | 9.2 % | 2.76 | — | 0.0 | 0.7 | 2.0 | — | — | -0.6 | — | 4.7 % | -103.4 % | 0.0 % | -39.6 % | -1.60 | — | -10.8 % | — | 0.0 % | 0.0 % | -29.5 | 19.1 % | 14.5 % | — |
| CTSO Cytosorbents Crp | 08/06 | -29 % | 98 11/22 | Stage 4 | D 39 | 4 of 9 | 0.0 $ | Medical Devices | – | — | — | Healthcare | 0.36 $ | -32.9 % | -44.6 % | -57.5 % | −64.6 % | +525.0 % | 4 | 42 | 18.1 % | 13.4 % | 1.39 | — | 7.2 | 0.7 | — | — | — | -1.9 | — | 71.0 % | -31.9 % | -141.6 % | -18.3 % | — | — | +4.1 % | — | 0.0 % | 0.0 % | -23.5 | 26.4 % | 3.6 % | — |
| SER Serina Therapeutics Inc | 08/10 | -32 % | 30 3/22 | Stage 4 | D 31 | 4 of 9 | 0.0 $ | Biotechnology | – | — | — | Healthcare | 2.00 $ | +0.4 % | -58.3 % | -63.9 % | −77.0 % | +422.0 % | 4 | 16 | 10.6 % | 9.9 % | 0.03 | — | 0.0 | 310.0 | 2.4 | — | — | 37.4 | — | -10,210.0 % | 0.0 % | -221.9 % | -89.8 % | 0.18 | — | +132.1 % | — | 0.0 % | 0.0 % | -3.6 | 9.8 % | 3.3 % | — |
| VERI Veritone Inc | 08/06 | -22 % | 20 3/25 | Stage 4 | D 29 | 4 of 9 | 0.1 $ | Software - Infrastructure | – | — | — | Technology | 1.10 $ | -69.5 % | -74.5 % | -50.9 % | −86.4 % | +476.2 % | 4 | 91 | 7.7 % | 7.5 % | 2.29 | — | 666.7 | 1.1 | 2.1 | — | — | 54.0 | — | 68.5 % | -123.8 % | -349.4 % | -27.8 % | 0.93 | — | -0.5 % | — | 0.0 % | 0.0 % | -14.4 | 25.7 % | 12.2 % | — |
| XCUR Exicure Inc | 08/14 | -25 % | 71 6/22 | Stage 4 | D 35 | 3 of 9 | 0.0 $ | Biotechnology | – | — | — | Healthcare | 1.60 $ | -49.6 % | -63.3 % | -77.6 % | −73.5 % | -20.6 % | 4 | 42 | 18.0 % | 12.5 % | 3.60 | — | 0.0 | — | — | — | — | 0.0 | — | — | 0.0 % | -145.2 % | -32.5 % | — | — | -100.0 % | — | 0.0 % | 0.0 % | -55.1 | 2.7 % | 0.5 % | — |
| VEEA Veea Inc. | 08/18 | — | 97 12/25 | Stage 4 | D 36 | 4 of 9 | 0.0 $ | Information Technology Services | – | — | — | Technology | 0.15 $ | -48.2 % | -60.7 % | -90.5 % | −84.5 % | — | 3 | 42 | 16.5 % | 14.0 % | 0.32 | — | 0.0 | 22.5 | — | — | — | 164.5 | — | 79.3 % | 0.0 % | 0.0 % | -42.4 % | — | — | +56.6 % | — | 0.0 % | 0.0 % | -25.4 | 3.2 % | 1.6 % | — |
| MVIS Microvision Inc | 08/06 | -31 % | 47 5/25 | Stage 4 | D 36 | 4 of 9 | 0.1 $ | Scientific & Technical Instruments | – | — | — | Technology | 0.27 $ | -58.5 % | -67.2 % | -76.0 % | −82.1 % | +545.2 % | 2 | 42 | 11.0 % | 10.1 % | 1.23 | — | 0.0 | 64.0 | — | — | — | -13.1 | — | -1,095.0 % | 0.0 % | -197.3 % | -41.9 % | — | — | -74.3 % | — | 0.0 % | 0.0 % | -30.1 | 25.9 % | 19.9 % | — |
| DOMO Domo Inc | — | -28 % | 20 3/25 | Stage 4 | C 47 | 4 of 9 | 0.2 $ | Software - Application | – | — | — | Technology | 3.70 $ | -73.4 % | -67.9 % | -77.6 % | −86.8 % | +77.6 % | 2 | 42 | 18.3 % | 12.0 % | 1.80 | — | 0.0 | 0.5 | — | 830.0 | — | -6.3 | — | 74.9 % | -17.4 % | 0.0 % | -10.5 % | — | — | +0.6 % | — | 0.0 % | 0.0 % | -33.1 | 65.1 % | 8.5 % | — |
| HRTX Heron Therapeuti | 08/14 | -22 % | 29 3/22 | Stage 4 | D 29 | 3 of 9 | 0.1 $ | Biotechnology | – | — | — | Healthcare | 0.50 $ | -67.8 % | -66.0 % | -71.3 % | −82.2 % | +387.8 % | 2 | 42 | 7.0 % | 8.8 % | 1.65 | — | 46.9 | 0.6 | — | — | — | 35.0 | — | 62.8 % | -20.5 % | -2,408.9 % | -2.7 % | — | — | +7.4 % | — | 0.0 % | 0.0 % | -19.6 | 83.3 % | 28.2 % | — |
| CDLX Cardlytics Inc | 08/05 | -32 % | 75 7/24 | Stage 4 | D 38 | 3 of 9 | 0.0 $ | Advertising Agencies | – | — | — | Communication Services | 3.70 $ | -53.6 % | -60.1 % | -81.7 % | −22.3 % | +116.3 % | 2 | 13 | 7.3 % | 9.4 % | 0.62 | — | 36.5 | 0.1 | 1.6 | 3.6 | — | -7.7 | — | 47.5 % | -44.8 % | -356.0 % | -7.7 % | -52.47 | — | -16.2 % | — | 0.0 % | 0.0 % | -14.8 | 29.9 % | 13.1 % | — |
| ELTX Elicio Therapeutics Inc. | 08/06 | -20 % | 57 5/22 | Stage 1 | E 22 | 3 of 9 | 0.1 $ | Biotechnology | – | — | — | Healthcare | 2.80 $ | -48.4 % | -51.2 % | -71.5 % | −76.6 % | +433.3 % | 2 | 42 | 34.2 % | 18.0 % | 1.79 | — | 0.0 | — | 99.1 | — | — | -2.6 | — | — | 0.0 % | -1,076.3 % | -92.4 % | -9.98 | — | -100.0 % | — | 0.0 % | 0.0 % | -41.0 | 17.0 % | 14.8 % | — |
| PSQH PSQ Holdings Inc. | 08/11 | -33 % | 20 3/25 | Stage 4 | C 45 | 4 of 9 | 0.0 $ | Software - Application | – | — | — | Technology | 4.10 $ | -56.7 % | -64.3 % | -86.5 % | −86.4 % | +1,053.8 % | 2 | 42 | 7.5 % | 8.0 % | 0.44 | — | 0.0 | 0.5 | — | — | — | -3.8 | — | 63.2 % | -165.6 % | -170.8 % | -29.4 % | — | — | -21.6 % | — | 0.0 % | 0.0 % | -8.8 | 15.6 % | 0.0 % | — |
| ADCT ADC Therapeutics SA | 08/11 | -15 % | 28 3/22 | Stage 4 | D 41 | 4 of 9 | 0.1 $ | Biotechnology | – | — | — | Healthcare | 1.10 $ | -67.4 % | -70.8 % | -62.1 % | −79.1 % | +380.8 % | 1 | 42 | 8.7 % | 10.5 % | 1.88 | — | 0.0 | 1.8 | 3.6 | — | — | -1.4 | — | -26.3 % | -173.0 % | -705.5 % | -22.7 % | -0.54 | — | +14.9 % | — | 0.0 % | 0.0 % | -13.1 | 67.6 % | 5.6 % | — |
| GOSS Gossamer Bio Inc | 08/04 | -29 % | 89 8/22 | Stage 4 | C 48 | 3 of 9 | 0.1 $ | Biotechnology | Uses AI | — | Healthcare | 0.17 $ | -94.5 % | -95.2 % | -91.7 % | −95.7 % | +2,168.2 % | 1 | 42 | 11.9 % | 13.1 % | 2.05 | — | 0.0 | 1.5 | 2.7 | — | — | -0.4 | — | 100.0 % | 0.0 % | -783.4 % | -52.3 % | -1.26 | — | -57.7 % | — | 0.0 % | 0.0 % | -40.3 | 75.2 % | 11.7 % | — | |
| MDXH MDxHealth SA ADR | 08/13 | -33 % | 7 1/22 | Stage 4 | C 46 | 4 of 9 | 0.0 $ | Diagnostics & Research | – | — | — | Healthcare | 0.42 $ | -85.6 % | -88.5 % | -82.5 % | −91.5 % | +544.4 % | 1 | 42 | 9.1 % | 10.9 % | -503,341.44 | — | 27.7 | 0.2 | 21.8 | — | — | 17.6 | — | 63.7 % | -29.9 % | -2,440.4 % | -6.4 % | -7.86 | — | +19.8 % | — | 0.0 % | 0.0 % | -6.8 | 48.5 % | 0.3 % | — |
Price Chart
Quarterly Figures
No quarterly data available.
Frequently Asked Questions
Altman's bankruptcy early warning in its purest form: the Z″-Score is in the distress zone (< 1.1) in both the most recent AND every available quarter, plus weak interest coverage (< 3). Unlike the stricter Going Concern scanner (which additionally requires negative operating cash flow), this scanner shows every stock that trades permanently in the red zone.
All scanners are recalculated daily across the entire stock universe — most recently on 3. August 2026. The data basis is fundamental data and SEC filings (10-K annual reports and 10-Q quarterly reports).
Currently, 92 stocks pass this scanner's criteria (as of 3. August 2026).
Global filters: market cap of $50B or less (mega caps are cut from every scanner); 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Fundamental Rating ≥ 55 out of 100) are excluded.
This scanner deliberately hunts for red flags — a hit is a finding, not a recommendation: like a smoke detector that beeps so you look in time. A hit is also not a bankruptcy verdict; most companies save themselves (say, through a capital raise, which dilutes existing shareholders). Portfolio owners use the list as an early-warning system, bargain hunters as an anti-shopping list, experienced traders as a watch list — it is never a buy or short recommendation.
Related scanners
- Bankruptcy Study: Stacked Warning Signals
- Below the 50- & 200-SMA
- Beneish M-Score
- Downward Momentum
- Going Concern (Distress Proxy)
- Insolvency Radar: Cash Running Low
- Kathy Donnelly: Liquid Movers Down
- Mike Webster: Overextended (Webby RSI)
- Near 52-Week Low
- Pradeep Bonde: $ Breakout Bearish
- Pradeep Bonde: 4% Breakout Bearish
- Qullamaggie: Parabolic (Short-Watch)
- RS Weakness (≤10)
- Stage 4 (Downtrend)
- Stan Weinstein: Stage 4
- Stan Weinstein: Stage 4B-
- Thomas Insolvency Candidate
- Weakness Cluster
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.